biostudies-literatureUnknownSuo YIntramural NIH HHSNCI NIH HHSNIGMS NIH HHSHyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood¹. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, causing a painful inflammatory disease known as gout. These conditions are associated with many other diseases and affect a significant and increasing proportion of the population^2-4. The human urate transporter 1 (URAT1) is responsible for the reabsorption of ~90% of uric acid in the kidneys back into the blood, making it a primary target for treating hyperuricemia and gout⁵. Despite decades of research and development, clinically available URAT1 inhibitors have limitations because the molecular basis of URAT1 inhibition by gout drugs remains unknown⁵. Here we present cryo-electron microscopy structures of URAT1 alone and in complex with three clinically relevant inhibitors: benzbromarone, lesinurad, and the novel compound TD-3. Together with functional experiments and molecular dynamics simulations, we reveal that these inhibitors bind selectively to URAT1 in inward-open states. Furthermore, we discover differences in the inhibitor dependent URAT1 conformations as well as interaction networks, which contribute to drug specificity. Our findings illuminate a general theme for URAT1 inhibition, paving the way for the design of next-generation URAT1 inhibitors in the treatment of gout and hyperuricemia.bioRxiv : the preprint server for biology2024.09.11.612563https://www.ebi.ac.uk/biostudies/studies/S-EPMC11419087biostudies-literatureMolecular basis of the urate transporter URAT1 inhibition by gout drugs.PMC11419087U24 GM12954775N91019D00024ZIC ES103326Zhan PTsolova KLee SYKumari SZhang HFedor JGIm WSharma KSuo YShi XBorgnia MfalseMolecular basis of the urate transporter URAT1 inhibition by gout drugs.Hyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood¹. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, causing a painful inflammatory disease known as gout. These conditions are associated with many other diseases and affect a significant and increasing proportion of the population^2-4. The human urate transporter 1 (URAT1) is responsible for the reabsorption of ~90% of uric acid in the kidneys back into the blood, making it a primary target for treating hyperuricemia and gout⁵. Despite decades of research and development, clinically available URAT1 inhibitors have limitations because the molecular basis of URAT1 inhibition by gout drugs remains unknown⁵. Here we present cryo-electron microscopy structures of URAT1 alone and in complex with three clinically relevant inhibitors: benzbromarone, lesinurad, and the novel compound TD-3. Together with functional experiments and molecular dynamics simulations, we reveal that these inhibitors bind selectively to URAT1 in inward-open states. Furthermore, we discover differences in the inhibitor dependent URAT1 conformations as well as interaction networks, which contribute to drug specificity. Our findings illuminate a general theme for URAT1 inhibition, paving the way for the design of next-generation URAT1 inhibitors in the treatment of gout and hyperuricemia.2024-01-01T00:00:00Z2024 Sep2026-04-21T03:30:40.431Z2025-04-06T14:24:02.752ZS-EPMC114190873931435210.1101/2024.09.11.612563